150 related articles for article (PubMed ID: 1998969)
1. A murine plasmacytoma MOPC 104E resistant to cyclophosphamide is resistant to immunotherapy.
Satoh K; Kan N; Okino T; Nakanishi M; Mise K; Teramura Y; Yamasaki S; Ohgaki K; Tobe T
Cancer Immunol Immunother; 1991; 32(5):273-9. PubMed ID: 1998969
[TBL] [Abstract][Full Text] [Related]
2. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
Nio Y; Ohgaki K; Tobe T
J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
[TBL] [Abstract][Full Text] [Related]
3. Immunoregulation of murine plasmacytoma. I. Generation of anomalous killer cells in vitro by cocultivation with MOPC 104E.
Hayashida I; Hiramoto RN; Shrestha K; Ghanta VK
Cancer Invest; 1989; 7(1):17-26. PubMed ID: 2567619
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes and in vivo IL2 against advanced murine plasmacytoma.
Kan N; Okino T; Nakanishi M; Sato K; Mise K; Yamasaki S; Teramura Y; Ohgaki K; Tobe T
Biotherapy; 1989; 1(3):197-206. PubMed ID: 2642023
[TBL] [Abstract][Full Text] [Related]
5. Two tumor models of curative adoptive chemoimmunotherapy using tumor-infiltrated spleen cells with potent antitumor cytotoxicity stimulated by antigen-sharing tumors.
Laude M; Russo KL; Mokyr MB; Dray S
Cancer Immunol Immunother; 1993 Jul; 37(2):89-96. PubMed ID: 8319246
[TBL] [Abstract][Full Text] [Related]
6. Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas.
Wise JA; Mokyr MB; Dray S
Cancer Immunol Immunother; 1988; 27(3):191-7. PubMed ID: 3263205
[TBL] [Abstract][Full Text] [Related]
7. Regulation of MOPC 104E by T cells and growth factors induced by C. parvum stimulation.
Shrestha K; Hiramoto RN; Ghanta VK
Int J Cancer; 1984 Jun; 33(6):845-50. PubMed ID: 6610653
[TBL] [Abstract][Full Text] [Related]
8. Host response to myeloma: effect of syngeneic spleen cells on the growth and function of MOPC 104E myeloma in vitro.
Miura T; Ghanta VK; Hiramoto RN
Cancer Invest; 1990; 8(1):17-25. PubMed ID: 2350718
[TBL] [Abstract][Full Text] [Related]
9. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
Weiskirch LM; Mokyr MB
Int J Cancer; 1992 Apr; 51(1):84-92. PubMed ID: 1563847
[TBL] [Abstract][Full Text] [Related]
10. Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. I. Methodological studies on the Winn assay.
Wang KC; Berczi I; Sehon AH
Int J Cancer; 1980 Apr; 25(4):487-92. PubMed ID: 7372372
[TBL] [Abstract][Full Text] [Related]
11. Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract.
Kan N; Ohgaki K; Inamoto T; Kodama H
Cancer Immunol Immunother; 1984; 18(3):215-22. PubMed ID: 6334553
[TBL] [Abstract][Full Text] [Related]
12. Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.
Barker E; Mokyr MB
Cancer Immunol Immunother; 1987; 25(3):215-24. PubMed ID: 3677124
[TBL] [Abstract][Full Text] [Related]
13. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.
Mokyr MB; Barker E
Cancer Immunol Immunother; 1986; 23(1):11-9. PubMed ID: 3490305
[TBL] [Abstract][Full Text] [Related]
14. Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor.
Weiskirch LM; Barker E; Mokyr MB
Cancer Immunol Immunother; 1990; 31(3):129-38. PubMed ID: 2337902
[TBL] [Abstract][Full Text] [Related]
15. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
[TBL] [Abstract][Full Text] [Related]
16. Therapy of the murine plasmacytoma MOPC 104E: role of the immune response.
Lubet RA; Carlson DE
J Natl Cancer Inst; 1978 Sep; 61(3):897-903. PubMed ID: 278867
[TBL] [Abstract][Full Text] [Related]
17. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
Adler A; Keisari Y; Ofir R
J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
[TBL] [Abstract][Full Text] [Related]
18. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
Barker E; Wise JA; Dray S; Mokyr MB
Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
[TBL] [Abstract][Full Text] [Related]
19. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor.
Gorelik L; Prokhorova A; Mokyr MB
Cancer Immunol Immunother; 1994 Aug; 39(2):117-26. PubMed ID: 8044831
[TBL] [Abstract][Full Text] [Related]
20. Analysis of effector cells in tumor-bearing mice pre-treated with active specific immunization followed by cyclophosphamide.
Li L; Okino T; Kan N; Yamasaki S; Ichinose Y; Sugie T; Kanaoka S; Imamura M
Biotherapy; 1998; 11(4):223-8. PubMed ID: 9950097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
